Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Progenics Pharm upgrade details — to Strong Buy at Needham ahead of pivotal Azdedra data, potential late 2017 launch; tgt raised to $14 (9.49)Needham upgrades PGNX to Strong Buy from Buy and raises their tgt to $14 from $11 noting they recently chose PGNX as their Top Pick for 2017 and are now going one step further and upgrading it to Strong Buy. They continue to expect significant appreciation in shares this year as the company launches its first wholly owned product and moves rapidly toward profitability. Their increased $14 price target reflects the introduction of ests for the 1404 imaging agent, which recently passed an interim analysis in its pivotal trial.</td> </tr></table>"